Display Options:

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Potassium chelating agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Esophageal Neoplasms; Graft vs Host Disease; Liver Diseases; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Carcinoma, Basal Cell; Leukemia; Medulloblastoma; Multiple Myeloma; Neoplasms

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Prostatic Neoplasms; Sexual Dysfunctions, Psychological

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Supplement
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Blood Coagulation Disorders; Coronary Disease; Hemorrhage; Ischemic Stroke; Myocardial Infarction; Peripheral Arterial Disease; Aortic Valve Stenosis; Atrial Fibrillation; Heart Diseases; Severe Acute Respiratory Syndrome; Stroke; Venous Thromboembolism; Thrombosis

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Smith-Lemli-Opitz Syndrome; Fatty Liver; Liver Diseases; Peroxisomal Disorders

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Postoperative Nausea and Vomiting; Nausea

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Neoplasms; Pulmonary Disease, Chronic Obstructive; Breast Neoplasms; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colonic Neoplasms; Nasopharyngeal Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Small Cell Lung Carcinoma; Urinary Bladder Neoplasms; Colorectal Neoplasms; Stomach Neoplasms

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cystic fibrosis transmembrane conductance regulator stabiliser
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Liver Diseases; Cystic Fibrosis

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hepatitis B, Chronic; Infections; Renal Insufficiency, Chronic; Hepatitis C; Hepatitis C, Chronic; Severe Acute Respiratory Syndrome; Virus Diseases

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: CDK6/cyclin D1 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Ductal; Carcinoma, Pancreatic Ductal; Glioblastoma; Head and Neck Neoplasms; Hereditary Breast and Ovarian Cancer Syndrome; Kidney Diseases; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma, Non-Hodgkin; Multiple Myeloma; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chordoma; Colonic Neoplasms; Endometrial Neoplasms; Liposarcoma; Lymphoma; Lymphoma, Mantle-Cell; Melanoma; Nasopharyngeal Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Osteosarcoma; Ovarian Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing; Severe Acute Respiratory Syndrome; Thymus Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Sarcoma; Breast Neoplasms; Neoplasms

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INHALATION
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Autistic Disorder; Brain Diseases; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Diabetes Mellitus, Type 2; Erectile Dysfunction; Hypovolemia; Ileus; Ischemia; Osteonecrosis; Reperfusion Injury; Respiratory Insufficiency; Aging; Angina, Stable; Brain Concussion; Brain Injuries; Breast Neoplasms; Carcinoma, Squamous Cell; Child Development Disorders, Pervasive; Colitis, Ulcerative; Death, Sudden, Cardiac; Endocarditis; Gliosarcoma; Idiopathic Pulmonary Fibrosis; Laryngeal Neoplasms; Lymphedema; Migraine Disorders; Multiple Myeloma; Myocardial Infarction; Neoplasms; Opioid-Related Disorders; Osteoradionecrosis; Pulmonary Fibrosis; Severe Acute Respiratory Syndrome; Sleep Apnea, Obstructive; Status Asthmaticus; Stress Disorders, Post-Traumatic; Stroke; Tinea Pedis; Tonsillitis; Urinary Tract Infections; Wounds and Injuries; Xerostomia; Acute Kidney Injury; Anemia, Sickle Cell; Bronchiolitis; Burns; Complex Regional Pain Syndromes; Coronary Disease; Diabetes Mellitus; Fractures, Bone; Heart Failure; Hypertension, Pulmonary; Infections; Ischemic Stroke; Optic Neuropathy, Ischemic; Pain; Pneumonia; Postoperative Nausea and Vomiting; Pregnancy; Premature Birth; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyoderma; Respiratory Distress Syndrome; Retinopathy of Prematurity; Schizophrenia; Sepsis; Shock; Ulcer; Vascular Diseases

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INHALATION
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cystic Fibrosis; Death, Sudden, Cardiac; Heart Failure; Obsessive-Compulsive Disorder; Pulmonary Disease, Chronic Obstructive; Reperfusion Injury; Stress Disorders, Post-Traumatic; Tinea Pedis; Burns; Colorectal Neoplasms; Keratosis, Actinic; Respiratory Insufficiency

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Pancreatic Ductal; Central Nervous System Neoplasms; Kidney Diseases; Liver Diseases; Lymphoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Follicular; Adrenal Cortex Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Cholangiocarcinoma; Chondrosarcoma; Glioma; Hepatitis B, Chronic; Hodgkin Disease; Kidney Neoplasms; Lung Neoplasms; Meningeal Carcinomatosis; Mesothelioma; Nasopharyngeal Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Retroviridae Infections; Sarcoma; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Melanoma; Stomach Neoplasms; Urinary Bladder Neoplasms; Neoplasms; Thyroid Neoplasms

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mu opioid receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Irritable Bowel Syndrome

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Anxiety Disorders; Bipolar Disorder; Child Development Disorders, Pervasive; Depressive Disorder; Depressive Disorder, Major; Schizophrenia; Psychotic Disorders

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Neprilysin inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Severe Acute Respiratory Syndrome; Aortic Valve Insufficiency; Cardiomyopathy, Hypertrophic; Essential Hypertension; Hypertension; Peripheral Arterial Disease; Chagas Cardiomyopathy; Hypertension, Pulmonary; Myocardial Infarction; ST Elevation Myocardial Infarction; Heart Failure

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Hepatitis C virus serine protease, NS3/NS4A inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hepatitis C; Hepatitis C, Chronic; Virus Diseases

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Nonstructural protein 5A inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hepatitis, Viral, Human; Hepatitis C; Hepatitis C, Chronic; Virus Diseases

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Integrin alpha-L/beta-2 (LFA-1) antagonist
ROUTE OF ADMINISTRATION: OPHTHALMIC
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Conjunctivitis, Allergic; Dry Eye Syndromes; Eye Diseases

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Nonstructural protein 5A inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hepatitis C; Hepatitis C, Chronic

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Synaptic vesicle glycoprotein 2A modulator
ROUTE OF ADMINISTRATION: INTRAVENOUS; ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Spinal Cord Injuries; Neuralgia, Postherpetic; Unverricht-Lundborg Syndrome; Epilepsy; Seizures

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Apoptosis regulator Bcl-2 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Amyloidosis, Familial; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Kidney Diseases; Leukemia; Leukemia, Prolymphocytic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Prostatic Neoplasms; Small Cell Lung Carcinoma; Blast Crisis; Breast Neoplasms; Hematologic Neoplasms; Leukemia, Biphenotypic, Acute; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Phosphodiesterase 4 inhibitor
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alopecia Areata; Dermatitis; Psoriasis; Scleroderma, Localized; Vitiligo; Dermatitis, Atopic; Eczema

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Glioblastoma; Glioma

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Pain; Blood Coagulation Disorders; Cognitive Dysfunction; Hemorrhage; Hypotension; Pre-Eclampsia; Cardiovascular Diseases; Nasal Obstruction; Obesity

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: PARP 1, 2 and 3 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Hereditary Breast and Ovarian Cancer Syndrome; Leiomyosarcoma; Mesothelioma; Pancreatic Neoplasms; Retroviridae Infections; Stomach Neoplasms; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms, Castration-Resistant; Neoplasms

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: VAGINAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Sarcoma, Synovial; Crohn Disease; Depressive Disorder; Erectile Dysfunction; HIV Infections; Hot Flashes; Multiple Myeloma; Myotonic Dystrophy; Primary Ovarian Insufficiency; Stress Disorders, Post-Traumatic; Substance Withdrawal Syndrome; Addison Disease; Adrenal Insufficiency; Aging; Anorexia Nervosa; Atrophic Vaginitis; Breast Neoplasms; Genital Neoplasms, Female; Infertility; Lupus Erythematosus, Systemic; Malaria; Menopause; Sexual Dysfunction, Physiological; Skin Aging; Arthritis, Rheumatoid; Dysmenorrhea; Hypogonadism; Klinefelter Syndrome; Neoplasms; Orchitis; Osteoarthritis; Pain

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bile acid receptor FXR agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Adenomatous Polyposis Coli; Cholestasis; Liver Diseases; Obesity; Pruritus; Barrett Esophagus; Cholangitis, Sclerosing; Diarrhea; Hepatitis, Alcoholic; Lipodystrophy, Familial Partial; Non-alcoholic Fatty Liver Disease; Cholangitis; Liver Cirrhosis, Biliary

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Parkinson Disease; Depressive Disorder, Major; Neurodegenerative Diseases; Schizophrenia; Psychotic Disorders

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Reducing agent
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Abscess; Glucosephosphate Dehydrogenase Deficiency; Jaundice; Sepsis; Alzheimer Disease; Malaria; Malaria, Falciparum; Severe Acute Respiratory Syndrome; Stress Disorders, Post-Traumatic; Tooth Diseases; Wounds and Injuries; Bipolar Disorder; Dysuria; Shock, Septic; Urinary Tract Infections

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA terminase inhibitor
ROUTE OF ADMINISTRATION: INTRAVENOUS; ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Pregnancy; Cytomegalovirus Infections; Infections; Virus Diseases

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Prostanoid FP receptor agonist
ROUTE OF ADMINISTRATION: OPHTHALMIC
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Carbepenem-hydrolyzing beta-lactamase KPC inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Bacterial Infections; Renal Insufficiency; Urinary Tract Infections

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Poly [ADP-ribose] polymerase 2 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Fallopian Tube Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma, Ewing; Stomach Neoplasms; Urogenital Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Glioblastoma; Head and Neck Neoplasms; Lymphoma; Melanoma; Mesothelioma; Pancreatic Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hereditary Breast and Ovarian Cancer Syndrome; Ovarian Neoplasms; Prostatic Neoplasms, Castration-Resistant; Small Cell Lung Carcinoma; Neoplasms